SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies

Individuals with hematological malignancies and hematopoietic stem cell transplant (HCT) recipients are immunologically heterogenous groups with varying degrees of immunosuppression at increased risk of severe disease and mortality from SARS-CoV-2 infection. SARS-CoV-2 vaccines are key interventions...

Full description

Saved in:
Bibliographic Details
Published in:Blood reviews 2022-11, Vol.56, p.100984, Article 100984
Main Authors: Ni, Bin, Yanis, Ahmad, Dee, Kevin, Chappell, James D., Dulek, Daniel E., Kassim, Adetola A., Kitko, Carrie L., Thomas, Lora D., Halasa, Natasha
Format: Article
Language:English
Subjects:
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
Graft vs Host Disease - etiology
Graft vs Host Disease - prevention & control
Hematologic malignancies
Hematologic Neoplasms - complications
Hematologic Neoplasms - therapy
Humans
Review
SARS-CoV-2
Stem cell transplantation
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Individuals with hematological malignancies and hematopoietic stem cell transplant (HCT) recipients are immunologically heterogenous groups with varying degrees of immunosuppression at increased risk of severe disease and mortality from SARS-CoV-2 infection. SARS-CoV-2 vaccines are key interventions to preventing severe COVID-19 and its complications. While these individuals were excluded from initial vaccine trials, there is now a growing body of acceptable safety and immunogenicity data among these individuals. A consistent signal for new or worsening graft versus host disease in allogeneic HCT recipients has not been demonstrated post-vaccination. Immunogenicity in these populations is variable depending on disease and treatment factors. However, serological responses may not accurately reflect vaccine protection as correlates of protection within these populations are not yet established. Large-scale studies powered to identify rare serious events, resolve differences in vaccine responses between different vaccination strategies, and identify immune correlates of protection within these populations are needed.
ISSN:0268-960X
1532-1681
DOI:10.1016/j.blre.2022.100984